WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events ...

Core Viewpoint - AtaiBeckley Inc has appointed Michael Faerm as Chief Financial Officer, effective March 9, 2026, to lead the company's financial strategy and operations as it advances its clinical-stage programs, particularly BPL-003 moving toward Phase 3 [1][4]. Group 1: Executive Appointment - Michael Faerm brings over 25 years of experience in life sciences, equity research, and investment banking to his new role as CFO [2]. - Anne Johnson, the current CFO since 2024, will transition to Chief Accounting Officer, ensuring continuity in financial operations [3]. Group 2: Company Strategy and Pipeline - AtaiBeckley focuses on developing rapid-acting, durable mental health treatments, with a pipeline that includes BPL-003 for treatment-resistant depression, VLS-01 for treatment-resistant depression, and EMP-01 for social anxiety disorder [5]. - BPL-003 is currently in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [5].

Core Insights - Seer, Inc. is participating in the 2026 U.S. Human Proteome Organization Annual Conference, showcasing its Proteograph Product Suite which addresses complex questions in major disease areas and supports clinical and population health applications [1][2] Company Participation and Presentations - Seer will be featured in over a dozen scientific presentations at the conference, highlighting the adoption of nanoparticle-enabled proteomics in translational and population-scale research [2][7] - The company will host a breakfast symposium on February 24, where Dr. Sasha A. Singh will present findings on using the Proteograph Product Suite to profile plasma in a mouse model of atherosclerosis, achieving a tenfold increase in proteome depth compared to conventional methods [5] Technological Advancements - The Proteograph Product Suite is enabling deeper, scalable, and reproducible mass spectrometry measurements of the human proteome, which is crucial for advancing translational research [4][10] - The technology allows for the quantification of over 5,000 proteins from just 75 µL of plasma, addressing challenges in detecting low-abundance proteins [5] Research Focus Areas - Presentations at the conference will cover various disease areas including cardiovascular disease, neurodegeneration, aging biology, and oncology, demonstrating the broad application of deep, scalable proteomics [2][7] - Nathan Basisty will discuss the translation of aging biology into biomarkers and therapeutic strategies during a plenary session, emphasizing the role of proteomic technologies [6] Industry Impact - The conference reflects a broader shift in proteomics towards high-throughput workflows that enhance biological insights across multiple disease areas [10] - Seer's technology is positioned as a key player in advancing the field of proteomics, supporting reproducible research at scale [4][11]

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Golf Entertainment Group Inc. (OTCQX: GLFE, GLFEP, GLFEO, GLFEN), a leading owner and operator of golf-focused leisure and entertainment businesses, has qualified to trade on the OTCQX® Best Market. Golf Entertainment Group Inc. upgraded to OTCQX from the OTCQB® Venture Market. Golf Entertainment Group Inc. begins trading today ...

Design win with Israel-based drone manufacturer for ISR Platform slated for deployment in India Accelerates Mobilicom’s commercial footprint in the high-growth APAC region Palo Alto, California, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mobilicom Limited (Nasdaq: MOB, MOBBW) (“Mobilicom” or the “Company”), a provider of cybersecurity and robust solutions for drones and robotics, today announced it has secured a design win with a new customer and initial order from a prominent Israel-based drone manufacturer, which ...

Core Viewpoint - Syndax Pharmaceuticals will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call and live audio webcast to discuss the results and provide a business update [1]. Group 1: Financial Results Announcement - The earnings release is scheduled for Thursday, February 26, 2026 [1]. - A conference call and live audio webcast will take place at 4:30 p.m. ET on the same day [1]. Group 2: Access Information - The live audio webcast and accompanying slides can be accessed through the Events & Presentations page in the Investors section of the Company's website [2]. - Conference ID for the call is Syndax4Q25, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800 [2]. - A replay of the conference call will be available approximately 24 hours after the event and will remain accessible for 90 days [2]. Group 3: Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3]. - Key products in the pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3]. - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3].

Core Insights - InterCure reports preliminary estimated revenue of NIS 265 million for 2025, marking an 11% increase compared to 2024, with nearly 20% revenue growth in the second half of 2025 [1][5] - The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA, indicating consistent financial performance [1][5] - Significant revenues were generated from the German market during the second half of 2025, highlighting successful market expansion efforts [1][4] Financial Highlights - Estimated annual revenue for 2025 is NIS 265 million, with approximately NIS 135 million generated in the second half [5] - Positive Adjusted EBITDA is expected in both halves of 2025, continuing the trend of financial stability [5] - Cash on hand as of December 31, 2025, is reported at NIS 43 million [5] Strategic Developments - The company resumed production, importation, and sales from the Nir Oz facility after disruptions due to the October 2023 attack [5] - InterCure launched over 70 new GMP SKUs in 2025, establishing category-leading positions in premium medical products [5] - A strategic acquisition of Botanico Ltd. is anticipated to enhance access to premium U.S. genetics and cultivation technologies, with expected revenues of over NIS 30 million in the second half of 2026 [5] - A partnership with Cannasoul R&D Ltd. was established, acquiring a 28% stake with an option to increase to 51%, enhancing research and pharmaceutical capabilities [5] Regulatory and Market Position - The company is closely monitoring regulatory developments in the U.S. regarding cannabis regulations, positioning itself to benefit from evolving market conditions [5] - InterCure's vertically integrated model and international partnerships are expected to drive long-term value for patients and shareholders [4][5]

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies through PLK1 inhibition [3] - The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a live webcast available for interested parties [1][2] Company Overview - Cardiff Oncology is advancing innovative cancer treatments, particularly targeting PLK1 inhibition, which is recognized as a validated oncology target with significant potential to change clinical practice [3] - The lead asset, onvansertib, is an oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large patient population with high unmet needs [3] - Onvansertib is also being investigated in other PLK1-driven cancers through ongoing investigator-initiated trials and has demonstrated robust clinical activity as a single agent in challenging tumors [3]

Core Viewpoint - Sprott Inc. reported significant growth in Assets Under Management (AUM) and net income for the year ended December 31, 2025, driven by market value appreciation and strong demand for precious metals and critical materials [2][11][20]. AUM Highlights - AUM reached $59.6 billion as of December 31, 2025, representing a 21% increase from $49.1 billion as of September 30, 2025, and an 89% increase from $31.5 billion as of December 31, 2024 [2][3]. - The growth in AUM was attributed to market value appreciation across fund products and $3.9 billion in net sales, particularly in the Exchange Listed Products segment [2][3]. Revenue Highlights - Management fees for the quarter were $63.8 million, up 54% from $41.4 million for the same quarter in 2024, and $199 million for the full year, up 28% from $155.3 million in 2024 [6]. - Carried interest and performance fees for the quarter were $38.1 million, a significant increase from $2.5 million in the same quarter of 2024, and $54.7 million for the full year, up from $7.3 million in 2024 [6]. - Total net revenues for the year were $285.1 million, compared to $178.7 million in 2024, reflecting strong performance across various segments [20]. Expense Highlights - Net compensation expense for the quarter was $20.9 million, up 22% from $17 million in the same quarter of 2024, and $75.1 million for the full year, up 12% from $66.8 million in 2024 [5]. - Stock-based compensation expense for the quarter was $28.2 million, significantly higher than $5 million in the same quarter of 2024, due to a transition to a cash-settled stock-based compensation plan [5][21]. - SG&A expenses were $5.1 million for the quarter, a slight increase from $4.9 million in the same quarter of 2024, while full-year SG&A expenses decreased to $18.5 million from $18.8 million in 2024 [7]. Earnings Summary - Net income for the quarter was $28.7 million ($1.11 per share), up from $11.7 million ($0.46 per share) in the same quarter of 2024, and $67.3 million ($2.61 per share) for the full year, up 37% from $49.3 million ($1.94 per share) in 2024 [11][22]. - Adjusted EBITDA for the quarter was $42.1 million ($1.63 per share), an 88% increase from $22.4 million ($0.88 per share) in the same quarter of 2024, and $121.4 million ($4.71 per share) for the full year, up 43% from $85.2 million ($3.35 per share) in 2024 [11][24]. Subsequent Events - As of February 13, 2026, AUM increased to $70.1 billion, reflecting an 18% rise from $59.6 billion as of December 31, 2025, driven by $7.7 billion in market value appreciation and $2.8 billion in net inflows [11]. - The Board of Directors announced a quarterly dividend of $0.40 per share on February 18, 2026 [11].

MONTREAL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce it has identified three new high priority lithium targets (area A, B and C in Figure 1) at the Anatacau Main Project, where drilling is currently underway, located in the Eeyou-Istchee James Bay region of Quebec. The Project is strategically situated 22 kilometers east and along strike of a major proven lithium-bearing structural corridor also hostin ...